Regeneron shares fall 12% on disappointing melanoma trial data
Regeneron shares fall 12% on disappointing melanoma trial data
Regeneron shares fall 12% on disappointing melanoma trial data
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.